Foundation Fighting Blindness
Foundation Fighting Blindness
Add to My Podcasts
Episodes
About
Reviews
Promote
Ocugen Launches Phase 2/3 Clinical Trial for Stargardt Disease Gene-Modifier Therapy
1 minutes
Posted Jul 21, 2025 at 2:42 pm.
0:00
1:43
Add to My Queue
Download
MP3
Share
episode
Share at current time
Show notes
The therapy delivers copies of the RORA gene to address multiple disease pathways.
Previous
Nanoscope Begins Rolling BLA Submission to FDA for Seeking Approval for its Optogenetic Therapy
Next
Eye on the Cure Podcast | Episode 89: Dr. Christine Curcio
← See all 261 episodes of Foundation Fighting Blindness
